UBS keeps Buy rating for Fresenius stock at EUR 56.00
Published on 10/01/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UBS maintained its Buy rating for Fresenius and kept its EUR 56.00 price target on September 17, 2026, according to Business Insider. The assessment gives the stock a defined reference point as Fresenius combines operational growth with further capacity investment in Europe.
UBS target stands above Xetra quote
The EUR 56.00 target lies 21.34 percent above the substitute Xetra price of EUR 46.15. The comparison uses the same euro currency and puts the analyst view beside the latest dated German-market quote rather than the company's operating figures.
Q2 growth reaches double digits
Fresenius reported revenue before special items of EUR 5.864 billion in the second quarter of 2026, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025. The company's EBIT before special items rose 10.00 percent to EUR 719.0 million from EUR 654.0 million, while core net income increased 14.00 percent to EUR 470.0 million from EUR 412.0 million, according to Fresenius.
The Q2 figures also showed growth across the main operating businesses. Kabi revenue reached EUR 2.244 billion, up 7.00 percent, while Helios revenue came to EUR 3.526 billion, up 5.00 percent, in the second quarter of 2026.
Capacity investment adds an execution test
Fresenius invested EUR 54.0 million in European infusion-solution capacity, opening a production line in Kutno, Poland, and expanding production and storage infrastructure in Isola della Scala, Italy, on September 25, 2026, as Finanznachrichten reported. The investment expands existing sites, so its financial contribution will depend on how quickly the additional capacity translates into delivered products and revenue.
Fresenius also plans to integrate its internal hospital services into Helios on January 1, 2027. The September 16, 2026 company notice said around 1,700 of more than 4,000 employees at Fresenius Health Services would move with their service companies to Helios.
Xetra quote remains below the analyst target
The substitute Xetra quote was last at EUR 46.15 on September 25, 2026 at 5:35 p.m. CEST, while the 200-day average stood at EUR 44.61. The next scheduled reporting date is November 4, 2026, when Fresenius plans to present its third-quarter results.
Price source: substitute price Xetra, Lang & Schwarz without data set.
Fresenius stock facts
- Company: Fresenius SE & Co. KGaA
- ISIN: DE0005785604
- WKN: 578560
- Ticker: FRE
- Primary exchange: Xetra
- Substitute price Xetra (as of September 25, 2026, 5:35 p.m. CEST): EUR 46.15
- Market capitalization: EUR 24.6 billion (as of October 1, 2026)
- 52-week range: EUR 35.11-52.96 (as of October 1, 2026)
- Sector / Industry: Healthcare / Medical - Care Facilities
- Index membership: DAX
- Next earnings date: November 4, 2026
